A Multi-center, Randomized Placebo-controlled Phase II Trial to Assess the Safety, Tolerability and Immunogenicity of Two Doses of the Candidate Vaccine MVA-SARS-2-S in Adults Aged 18 to 64 and 65 and Older

UKE-SARS-COV-2-II

In this multi-center phase II clinical trial, adults in stable health conditions will be vaccinated twice with either a low dose or high dose of the candidate vaccine MVA-SARS-2-S, or placebo. The aim of the study is to assess the safety and immunogenicity of the candidate vaccine.

2021-01-15

2022-11-02

2022-11-02

Withdrawn

Early phase I

Inclusion Criteria: 1. Written informed consent. 2. Male and female adults in stable health conditions aged 18 - 64 at time of informed consent (participation of health care workers and risk groups will be prioritized) and male or female in stable health conditions aged ≥ 65 at time of informed consent. 3. Either in good or stable health in the opinion of the investigator. Participants may have underlying illness as long as their symptoms are medically controlled, and they are on a stable medication for the respective underlying illness for at least 8 weeks before screening and no changes are expected during the study. 4. Body mass index 18.5 - 32.0 kg/m2 and weight \> 50 kg at screening. 5. Non-pregnant, non-lactating female with negative pregnancy test. 6. Females who agree to comply with the applicable contraceptive requirements of the protocol. Exclusion Criteria: 1. Receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination. 2. Previous rMVA immunization. 3. Evidence of an active SARS-CoV-2 infection. 4. Known allergy to the components of the MVA-SARS-2-S vaccine product such as chicken proteins, or history of life-threatening reactions to vaccine containing the same substances. 5. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. 6. Evidence in the participant's medical history or in the medical examination that might influence either the safety of the participant or the absorption, distribution, metabolism or excretion of the investigational product under investigation. 7. Clinically relevant findings in ECG or significant thromboembolic events in medical history. 8. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes (HbA1c \> 7.0). 9. Any known chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Male and female individuals in stable health conditions (group I and II, see below) will be stratified for age and included to the following groups with a random allocation to one of the two dose groups or the placebo in a 4:4:1 ratio:\n\n* 1 x 107 ± 0.5 log IU MVA-SARS-2-S\n* 1 x 108 ± 0.5 log IU MVA-SARS-2-S\n* Placebo\n\nMale and female individuals in stable health conditions will be stratified for age and randomized to low dose, hogh dose of MVA SARS-2-S or the placebo in a 4:4:1 ratio:\n\n* 1 x 107 ± 0.5 log IU MVA-SARS-2-S\n* 1 x 108 ± 0.5 log IU MVA-SARS-2-S\n* Placebo', 'primaryPurpose': 'PREVENTION', 'maskingInfo': {'masking': 'TRIPLE', 'maskingDescription': 'Double-blind: two or more parties are unaware of the intervention assignment.', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 0, 'type': 'ACTUAL'}}

2023-07-18